Citations

Mayo Clinic

Showing 10 of 108599 citations.

Recurrent Tumefactive Central Nervous System Lesions Due to BRIP1-Related Fanconi Anemia
Nathoo, Nabeela , Gavrilova, Ralitza H. , Trejo‐Lopez, Jorge , Alqallaf, Abdulradha, Nathoo, Nabeela , McGarrah, Patrick W. , Go, Ronald S. , Tobin, W. Oliver

The Neurologist | August 15, 2023 | Volume: 28 | Issue: 5 | Pages: 332-334

10.1097/nrl.0000000000000511 | PMID 37582649 Get It

Introduction: Fanconi anemia (FA) is an inherited condition associated with genetic mutations that affect DNA repair proteins. More than 20 genes involved in the FA/BRCA pathway have been implicated in FA, including BRIP1. Tumefactive brain lesions are rare in FA. Case Report: We describe a patient with FA and recurrent tumefactive brain lesions preceded by calcifications on head computed tomography. A biopsy revealed white-matter gliosis with severe vasculopathy. Whole-genome sequencing demonstrated a BRIP1 homozygous variant with a final diagnosis of recurrent tumefactive brain lesions due to BRIP1-associated CNS vasculopathy. Immunosuppressive treatment was ineffective in the present case. Conclusions: Mechanistically, the specific role of BRIP1 mutation in CNS inflammation and vasculopathy is unclear. However, immunodeficiency disorders can lead to autoimmunity and/or immune dysregulation due to the possible loss or gain of function of components of the immune system.
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
Sandborn, William J. , Chen, Jingjing , Kisfalvi, Krisztina, Loftus, Edward V. , D’Haens, Geert , Candela, Ninfa , Lasch, Karen, Wolf, Douglas C. , Uddin, Sharif , Danese, Silvio , Loftus, Edward V , Danese, Silvio

Crohn's & Colitis 360 | August 15, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad034 | PMID 37636008 Get It

Abstract Background Vedolizumab, an anti-α4β7 integrin approved for intravenous (IV) treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), was evaluated as a subcutaneous (SC) formulation in maintenance therapy for UC and CD in phase 3 VISIBLE 1, 2, and open-label extension studies, and recently approved in Europe, Australia, and Canada. Our aim was to evaluate efficacy and safety of IV and SC vedolizumab in clinically relevant UC and CD scenarios. Methods Post hoc data analyses from VISIBLE trials examined: (1) whether baseline characteristics predict clinical response to 2 vs 3 IV vedolizumab induction doses; (2) efficacy and safety of switching during maintenance vedolizumab IV to SC in patients with UC; (3) vedolizumab SC after treatment interruption of 1–46 weeks; (4) increasing dose frequency of vedolizumab SC from every 2 weeks (Q2W) to every week (QW) after disease worsening. Results No baseline characteristics were identified as strong predictors of response to 2 vs 3 vedolizumab infusions. Most patients achieved clinical response after 2 or 3 doses of IV vedolizumab maintained with SC treatment. Clinical remission and response rates were maintained in patients transitioned from maintenance vedolizumab IV to SC treatment. Of patients with UC, ≥75% achieved response following resumption after dose interruption. Escalation to QW dosing resulted in ≥45% of patients regaining response after loss while receiving vedolizumab Q2W. Conclusions Clinical real-world scenarios with vedolizumab SC were reviewed using VISIBLE studies data. Vedolizumab SC provides an additional dosing option for patients with UC and CD.
Hemodynamic Predictors of Outcome Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Alabdaljabar, Mohamad S. , Cendrowski, Emily , Nishimura, Rick A. , Miranda, William R. , Geske, Jeffrey B. , Rihal, Charanjit S. , Eleid, Mackram F. , Cendrowski, Emily E , Geske, Jeffrey B , Alabdaljabar, Mohamad S , Nishimura, Rick A , Rihal, Charanjit S.

Circulation: Cardiovascular Interventions | August 15, 2023 | Volume: 16 | Issue: 8 | Pages: No page available

10.1161/circinterventions.123.013068 | PMID 37582173 Get It

BACKGROUND: Alcohol septal ablation (ASA) is a minimally invasive treatment for drug-refractory obstructive hypertrophic cardiomyopathy. Detailed assessment of pressure changes and predictors of mortality and procedure success are not well defined. METHODS: This is a single-center study evaluating pressure changes and predictors of mortality and procedure success in transseptal ASA. Survival analysis and predictors of mortality were assessed using the Kaplan-Meier analysis and Cox regression, respectively. RESULTS: A total of 156 patients were included (mean age, 67.3 years; 46.8% women). Left atrial (LA) pressure and left ventricular outflow tract (LVOT) gradient decreased, whereas aortic pulse pressure (PP) increased post-ASA. Patients with lower baseline mean LA pressure (<median, 19 mm Hg), LVOT gradient reduction >82% (gradient change median), and PP increase >19% (PP change median) had superior survival. On Cox univariable regression, baseline mean LA pressure >median (19 mm Hg; hazard ratio [HR], 2.09 [95% CI, 1.05–4.18]; P =0.036), residual LVOT gradient (HR, 1.02 [95% CI, 1.01–1.03]; P =0.003), and LVOT gradient percent reduction <median (82%; HR, 2.92 [95% CI, 1.46–5.83]; P =0.002) were predictors of mortality. When adjusting for age and sex, baseline LA v wave >median (28 mm Hg; HR, 2.36 [95% CI, 1.17–4.76]; P =0.016), baseline mean LA pressure >median (19 mm Hg; HR, 2.70 [95% CI, 1.33–5.50]; P =0.006), percentage reduction in gradient <median (82%; HR, 2.74 [CI, 1.37–5.50]; P =0.005), and percentage increase in PP <median (19.3%; HR, 2.09 [CI, 1.05–4.16]; P =0.035) predicted survival free of all-cause mortality. CONCLUSIONS: ASA is associated with an acute decrease in the LVOT gradient and LA pressures and increase in aortic PP. Mean LA pressure, percentage decrease in LVOT gradient, and increase in PP are strong predictors of survival free of all-cause mortality following ASA and are important variables for procedural guidance.
Uptake of Biosimilar Among Privately Insured Patients Undergoing Infliximab Treatment
Chang, Jessica , Karaca‐Mandic, Pinar , Jeffery, Molly Moore

Medical Care | August 15, 2023 | Volume: 61 | Issue: 10 | Pages: 636-643

10.1097/mlr.0000000000001906 | PMID 37582298 Get It

Background: Recent literature has found rapid uptake of short-acting filgrastim biosimilars but slower uptake of other biosimilars, such as infliximab, in both Medicare and privately insured enrollees. Objectives: To describe patient, provider, and health plan characteristics associated with a switch to biosimilar among existing infliximab patients. Research Design: We constructed a retrospective panel dataset of patients undergoing active infliximab treatments and the choice of infliximab drug for each infusion. We used mixed logit regression controlling for patient, provider, and health plan characteristics as well as time-fixed effects. Subjects: Medicare Advantage and privately insured enrollees with evidence of active infliximab treatments between 2016 and 2020 (n=357,430). Measures: Our primary outcome of interest was to switch from infliximab originator to one of the infliximab biosimilars. Exposure variables of interest variables such as out-of-pocket, site of care, and in-network deductible. Results: Our study found nominally low switching among existing infliximab originator users (3.4%). We found that patients who previously received 1 infliximab originator infusion were 63.7% more likely to switch to biosimilar compared with patients who previously received administration of 20 infliximab originators. We found that biosimilar’s placement as health’s plan preferred drug was attributed to higher likelihood of biosimilar use (odds ratio: 1.666; P -value=0.001). We did not observe any statistically significant effect among out-of-pocket amount or deductible with respect to switch to infliximab biosimilar. Conclusions: To encourage uptake and switch to biosimilar, policymakers should consider targeted policies that include leveraging health plan tools such as placement of biosimilar as preferred drug and aim to educate patients on the clinical equivalence between infliximab biosimilar and originator.
Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak
Halasa, Natasha , Zambrano, Laura D. , Stewart, Laura S , Newhams, Margaret M. , Levy, Emily R. , Carroll, Christopher L. , Fitzgerald, Julie C. , Bline, Katherine , Cullimore, Melissa L. , Loftis, Laura L. , Jeyapalan, Asumthia , Schwarz, Adam J. , Zinter, Matt S. , Irby, Katherine , Kuebler, Joseph D. , Babbitt, Christopher , Gaspers, Mary Glas , Nofziger, Ryan A. , Kong, Michele , Coates, Bria M. , Schuster, Jennifer E. , Gertz, Shira J. , Mack, Elizabeth H. , White, Benjamin R. , Harvey, Helen , Butler, Andrew , Bradford, Tamara T. , Rowan, Courtney M. , Staat, Mary Allen , Aguiar, Cassyanne L. , Randolph, Adrienne G. , Campbell, Angela P. , Investigators, RSV-PIC, Tomcany, Merry, Price, Heather E. , Sanders, Ronald C., Dixon, Lexie, Kücükak, Suden, McNamara, Elizabeth R, Chen, Sabrina R., Listerud, Eve, Vargas-Shiraishi, Ofelia, Oberle, Betty, Zorensky, Frances, Mansour, Rachel, Jumarang, Jaycee , Johnston, Marla , Bush, Jenny L., Dickey, Shawn, Sullivan, Melissa, Kietzman, Abigail , Colston, Candice , Murdock, Meghan, Kelley, Heather M., Wright-Sexton, Laura, Martin, Maygan, Malloch, Lacy , Patterson, Kayla, Sanders, Cameron , Rohlfs, Chelsea , Rice, Marilyn, Howard, Miranda, Murphy, M. Gail, Soma, Vijaya L, Job, Megan , Mennie, Colleen, Simkhada, Kamala, Drapeau, Noelle M., Hayek, Haya , Maranto, Molly, Waters, Aubrie, Flowers, Maggie, Havlin, Kevin , Furlong-Dillard, Jamie , Porter, Melissa , Nason, Jennifer, Ray, Madison, Gossett, Kristen, Crandall, Hillary , Heller, Evan G, Foley, Jennifer, Rasal, Rajashri, Marlow, Christine, Senthil, Anurithi, Myers, Kimberly, Tudor, Betsy, Garcia, Nereyda, Treister, Natalie, Sun, Kathleen, Villarreal-Chico, Denise, Kainaroi, Sophia, Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Staat, Mary A , Gertz, Shira J , Bline, Katherine E , Amarin, Justin Z. , Shein, Steven L. , Michaels, Marian G , Montgomery, Vicki , Pannaraj, Pia S. , Cvijanovich, Natalie Z , Maddux, Aline B. , Bembea, Melania M. , Zerr, Danielle M. , Hobbs, Charlotte V. , Dapul, Heda , Wellnitz, Kari , Hymes, Saul , Investigators, RSV-PIC, Michelson, Kelly Nicole , Typpo, Katri , Harwayne‐Gidansky, Ilana , Bush, Jenny, Hill, Shannon, Kelley, Heather, Martin, Lora , Rice, Marilyn, Howard, Miranda, Murphy, Makayla, Ratner, Adam J. , Behl, Supriya , Betters, Kristina Ann , Maranto, Molly , Nason, Jennifer, Marlow, Christine, Myers, Kimberly, Adler, Amanda , Garcia, Nereyda, McQuillen, Patrick S. , Williams, John V.

JAMA Network Open | August 15, 2023 | Volume: 6 | Issue: 8 | Pages: e2328950

10.1001/jamanetworkopen.2023.28950 | PMID 37581884 Get It

ImportanceRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) and infant hospitalization worldwide.ObjectiveTo evaluate the characteristics and outcomes of RSV-related critical illness in US infants during peak 2022 RSV transmission.Design, Setting, and ParticipantsThis cross-sectional study used a public health prospective surveillance registry in 39 pediatric hospitals across 27 US states. Participants were infants admitted for 24 or more hours between October 17 and December 16, 2022, to a unit providing intensive care due to laboratory-confirmed RSV infection.ExposureRespiratory syncytial virus.Main Outcomes and MeasuresData were captured on demographics, clinical characteristics, signs and symptoms, laboratory values, severity measures, and clinical outcomes, including receipt of noninvasive respiratory support, invasive mechanical ventilation, vasopressors or extracorporeal membrane oxygenation, and death. Mixed-effects multivariable log-binomial regression models were used to assess associations between intubation status and demographic factors, gestational age, and underlying conditions, including hospital as a random effect to account for between-site heterogeneity.ResultsThe first 15 to 20 consecutive eligible infants from each site were included for a target sample size of 600. Among the 600 infants, the median (IQR) age was 2.6 (1.4-6.0) months; 361 (60.2%) were male, 169 (28.9%) were born prematurely, and 487 (81.2%) had no underlying medical conditions. Primary reasons for admission included LRTI (594 infants [99.0%]) and apnea or bradycardia (77 infants [12.8%]). Overall, 143 infants (23.8%) received invasive mechanical ventilation (median [IQR], 6.0 [4.0-10.0] days). The highest level of respiratory support for nonintubated infants was high-flow nasal cannula (243 infants [40.5%]), followed by bilevel positive airway pressure (150 infants [25.0%]) and continuous positive airway pressure (52 infants [8.7%]). Infants younger than 3 months, those born prematurely (gestational age &amp;lt;37 weeks), or those publicly insured were at higher risk for intubation. Four infants (0.7%) received extracorporeal membrane oxygenation, and 2 died. The median (IQR) length of hospitalization for survivors was 5 (4-10) days.Conclusions and RelevanceIn this cross-sectional study, most US infants who required intensive care for RSV LRTIs were young, healthy, and born at term. These findings highlight the need for RSV preventive interventions targeting all infants to reduce the burden of severe RSV illness.
Evidence-based clinical practice guidelines on postdural puncture headache: a consensus report from a multisociety international working group
Uppal, Vishal , Russell, Robin , Sondekoppam, Rakesh V. , Ansari, Jessica , Baber, Zafeer, Chen, Yian , DelPizzo, Kathryn , Kalagara, Hari , Kissoon, Narayan , Leffert, Lisa , Μoka, Εleni , Rodriguez, Stephen E. , Dirzu, Dan Sebastian , Kalagara, Hari , Kissoon, Narayan R , Kranz, Peter G , Leffert, Lisa , Lim, Grace , Lobo, Clara , Lucas, Dominique Nuala , Moka, Eleni , Rodriguez, Stephen E , Sehmbi, Herman , Vallejo, Manuel C , Volk, Thomas , Narouze, Samer , Uppal, Vishal , Sondekoppam, Rakesh V , Dîrzu, Dan Sebastian , Kranz, Peter G. , Lobo, Clara , Volk, Thomas , Narouze, Samer

Regional Anesthesia & Pain Medicine | August 15, 2023 | Volume: 49 | Issue: 7 | Pages: 471-501

10.1136/rapm-2023-104817 | PMID 37582578 Get It

Introduction Postdural puncture headache (PDPH) can follow unintentional dural puncture during epidural techniques or intentional dural puncture during neuraxial procedures such as a lumbar puncture or spinal anesthesia. Evidence-based guidance on the prevention, diagnosis or management of this condition is, however, currently lacking. This multisociety guidance aims to fill this void and provide practitioners with comprehensive information and patient-centric recommendations to prevent, diagnose and manage patients with PDPH. Methods Based on input from committee members and stakeholders, the committee cochairs developed 10 review questions deemed important for the prevention, diagnosis and management of PDPH. A literature search for each question was performed in MEDLINE (Ovid) on 2 March 2022. The results from each search were imported into separate Covidence projects for deduplication and screening, followed by data extraction. Additional relevant clinical trials, systematic reviews and research studies published through March 2022 were also considered for the development of guidelines and shared with contributors. Each group submitted a structured narrative review along with recommendations graded according to the US Preventative Services Task Force grading of evidence. The interim draft was shared electronically, with each collaborator requested to vote anonymously on each recommendation using two rounds of a modified Delphi approach. Results Based on contemporary evidence and consensus, the multidisciplinary panel generated 50 recommendations to provide guidance regarding risk factors, prevention, diagnosis and management of PDPH, along with their strength and certainty of evidence. After two rounds of voting, we achieved a high level of consensus for all statements and recommendations. Several recommendations had moderate-to-low certainty of evidence. Conclusions These clinical practice guidelines for PDPH provide a framework to improve identification, evaluation and delivery of evidence-based care by physicians performing neuraxial procedures to improve the quality of care and align with patients’ interests. Uncertainty remains regarding best practice for the majority of management approaches for PDPH due to the paucity of evidence. Additionally, opportunities for future research are identified.
The Evolving Role of Surgical Aortic Valve Replacement in the Era of Transcatheter Valvular Procedures
Juarez-Casso, Fernando M. , Crestanello, Juan A.

Journal of Clinical Medicine | August 15, 2023 | Volume: 12 | Issue: 16 | Pages: 5299

10.3390/jcm12165299 | PMID 37629341 Get It

Surgical aortic valve replacement (SAVR) has long been the standard treatment for severe symptomatic aortic stenosis (AS). However, transcatheter aortic valve replacement (TAVR) has emerged as a minimally invasive alternative; it was initially intended for high-risk patients and has now expanded its use to patients of all risk groups. While TAVR has demonstrated promising outcomes in diverse patient populations, uncertainties persist regarding its long-term durability and potential complications, raising the issue of the ideal lifetime management strategy for patients with AS. Therefore, SAVR continues to play an important role in clinical practice, particularly in younger patients with longer life expectancies, those with complex aortic anatomy who are unsuitable for TAVR, and those requiring concomitant surgical procedures. The choice between TAVR and SAVR warrants personalized decision-making, considering patient characteristics, comorbidities, anatomical considerations, and overall life expectancy. A multidisciplinary approach involving an experienced heart team is crucial in the preoperative evaluation process. In this review, we aimed to explore the current role of surgical management in addressing aortic valve stenosis amidst the expanding utilization of less invasive transcatheter procedures.
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Ou, Fang‐Shu , Ahn, Daniel H. , Dixon, Jesse G. , Lou, Yiyue , Hubbard, Joleen M. , Goldberg, Richard M. , Hoff, Paulo M. , Douillard, Jean‐Yves , Hecht, J. Randolph , Hurwitz, Herbert I. , Punt, Cornelis J.A. , Koopman, Miriam , Bokemeyer, Carsten , Fuchs, Charles S. , Cremolini, Chiara , Kabbinavar, Fairooz F. , Bekaii‐Saab, Tanios , Chibaudel, Benoist , Zalcberg, John , Adams, Richard , Gramont, Aimery de , Shi, Qian , Kasi, Pashtoon Murtaza , Hubbard, Joleen , Goldberg, Richard M , Bokemeyer, Carsten , Zalcberg, John , Adams, Richard , Shi, Qian , Ou, Fang-Shu , Bekaii-Saab, Tanios S , Cremolini, Chiara , Chibaudel, Benoist , Dixon, Jesse G , Grothey, Axel , Cutsem, Eric Van , Saltz, Leonard B. , Schmoll, Hans‐Joachim , Venook, Alan P. , Díaz‐Rubio, Eduardo , Tebbutt, Niall C. , Yoshino, Takayuki

Cancers | August 15, 2023 | Volume: 15 | Issue: 16 | Pages: 4117

10.3390/cancers15164117 | PMID 37627145 Get It

Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS). Patients and Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the 12-week scan. Lesion-based response criteria were defined for each patient as follows: PL only, SL only, RL only, and varied responses (mixture of RL, SL, and PL). Lesion-based response criteria and OS were correlated using stratified multivariable Cox models. The concordance between OS and classifications was measured using the C statistic. Results: Among 10,551 patients with mCRC from 17 first-line studies, varied responses were noted in 51.6% of patients, among whom, 3.3% had RL/PL at 12 weeks. Among patients with RL/SL, 52% had stable disease (SD) by RECIST 1.1, and they had a longer OS (median OS (mOS) = 19.9 months) than those with SL only (mOS = 16.8 months, HR (95% CI) = 0.81 (0.76, 0.85), p < 0.001), although a shorter OS than those with RL only (mOS = 25.8 months, HR (95% CI) = 1.42 (1.32, 1.53), p < 0.001). Among patients with SL/PL, 74% had SD by RECIST 1.1, and they had a longer OS (mOS = 9.0 months) than those with PL only (mOS = 8.0 months, HR (95% CI) = 0.75 (0.57, 0.98), p = 0.040), yet a shorter OS than those with SL only (mOS = 16.8 months, HR (95% CI) = 1.98 (1.80, 2.18), p < 0.001). These associations were consistent across treatment regimen subgroups. The lesion-based response criteria showed slightly higher concordance than RECIST 1.1, although it was not statistically significant. Conclusion: Varied responses at first restaging are common among patients receiving first-line therapy for mCRC. Our lesion-based measurement criteria allowed for better mortality discrimination, which could potentially be informative for treatment decision-making and influence patient outcomes.
A Multidimensional Connectomics- and Radiomics-Based Advanced Machine-Learning Framework to Distinguish Radiation Necrosis from True Progression in Brain Metastases
Cao, Yilin , Parekh, Vishwa S. , Chen, Xuguang , Pillai, Jay J. , Peng, Luke , Jacobs, Michael A. , Kleinberg, Lawrence , Chen, Xuguang , Pillai, Jay J , Jacobs, Michael A , Kleinberg, Lawrence R , Lee, Emerson E. , Redmond, Kristin Janson

Cancers | August 15, 2023 | Volume: 15 | Issue: 16 | Pages: 4113

10.3390/cancers15164113 | PMID 37627141 Get It

We introduce tumor connectomics, a novel MRI-based complex graph theory framework that describes the intricate network of relationships within the tumor and surrounding tissue, and combine this with multiparametric radiomics (mpRad) in a machine-learning approach to distinguish radiation necrosis (RN) from true progression (TP). Pathologically confirmed cases of RN vs. TP in brain metastases treated with SRS were included from a single institution. The region of interest was manually segmented as the single largest diameter of the T1 post-contrast (T1C) lesion plus the corresponding area of T2 FLAIR hyperintensity. There were 40 mpRad features and 6 connectomics features extracted, as well as 5 clinical and treatment factors. We developed an Integrated Radiomics Informatics System (IRIS) based on an Isomap support vector machine (IsoSVM) model to distinguish TP from RN using leave-one-out cross-validation. Class imbalance was resolved with differential misclassification weighting during model training using the IRIS. In total, 135 lesions in 110 patients were analyzed, including 43 cases (31.9%) of pathologically proven RN and 92 cases (68.1%) of TP. The top-performing connectomics features were three centrality measures of degree, betweenness, and eigenvector centralities. Combining these with the 10 top-performing mpRad features, an optimized IsoSVM model was able to produce a sensitivity of 0.87, specificity of 0.84, AUC-ROC of 0.89 (95% CI: 0.82–0.94), and AUC-PR of 0.94 (95% CI: 0.87–0.97).
Consensus Practice Guidelines on Postdural Puncture Headache From a Multisociety, International Working Group
Sondekoppam, Rakesh V. , Ansari, Jessica , Baber, Zafeer, Chen, Yian, DelPizzo, Kathryn , Kalagara, Hari , Leffert, Lisa , Μoka, Εleni , Rodriguez, Stephen E. , Kalagara, Hari , Moka, Eleni , Rodriguez, Stephen E , Sondekoppam, Rakesh V , Uppal, Vishal , Russell, Robin , Chen, Yian, Dîrzu, Dan Sebastian , Kissoon, Narayan , Kranz, Peter G. , Lim, Grace , Lobo, Clara , Lucas, Dominique Nuala , Sehmbi, Herman , Vallejo, Manuel C , Volk, Thomas , Narouze, Samer

JAMA Network Open | August 15, 2023 | Volume: 6 | Issue: 8 | Pages: e2325387

10.1001/jamanetworkopen.2023.25387 | PMID 37581893 Get It

Importance Postdural puncture headache (PDPH) can follow unintentional dural puncture during epidural techniques or intentional dural puncture during neuraxial procedures, such as a lumbar puncture or spinal anesthesia. Evidence-based guidance on the prevention, diagnosis, and management of this condition is, however, currently lacking. Objective To fill the practice guidelines void and provide comprehensive information and patient-centric recommendations for preventing, diagnosing, and managing PDPH. Evidence Review With input from committee members and stakeholders of 6 participating professional societies, 10 review questions that were deemed important for the prevention, diagnosis, and management of PDPH were developed. A literature search for each question was performed in MEDLINE on March 2, 2022. Additional relevant clinical trials, systematic reviews, and research studies published through March 2022 were also considered for practice guideline development and shared with collaborator groups. Each group submitted a structured narrative review along with recommendations that were rated according to the US Preventive Services Task Force grading of evidence. Collaborators were asked to vote anonymously on each recommendation using 2 rounds of a modified Delphi approach. Findings After 2 rounds of electronic voting by a 21-member multidisciplinary collaborator team, 47 recommendations were generated to provide guidance on the risk factors for and the prevention, diagnosis, and management of PDPH, along with ratings for the strength and certainty of evidence. A 90% to 100% consensus was obtained for almost all recommendations. Several recommendations were rated as having moderate to low certainty. Opportunities for future research were identified. Conclusions and Relevance Results of this consensus statement suggest that current approaches to the treatment and management of PDPH are not uniform due to the paucity of evidence. The practice guidelines, however, provide a framework for individual clinicians to assess PDPH risk, confirm the diagnosis, and adopt a systematic approach to its management.